Drug General Information
Drug ID	D0PU8Z
Former ID	DCL000511
Drug Name	Dacetuzumab
Drug Type	Monoclonal antibody
Indication	Large B-cell lymphoma; Non-hodgkin's lymphoma [ICD9: 202.8; ICD10:C81-C86]		Terminated	[537129]
Company	Roche; Genentech
Structure		Download 2D MOL 3D MOL
Formula	C26H29ClN2O4
PubChem Compound ID	23581811
Target and Pathway
Target(s)	Tumor necrosis factor ligand superfamily member 5	Target Info	Modulator
KEGG Pathway	Cytokine-cytokine receptor interaction
	NF-kappa B signaling pathway
	Cell adhesion molecules (CAMs)
	T cell receptor signaling pathway
	Intestinal immune network for IgA production
	Malaria
	Toxoplasmosis
	Asthma
	Autoimmune thyroid disease
	Systemic lupus erythematosus
	Allograft rejection
	Primary immunodeficiency
	Viral myocarditis
NetPath Pathway	IL2 Signaling Pathway
	TNFalpha Signaling Pathway
	TCR Signaling Pathway
Pathway Interaction Database	IL4-mediated signaling events
	CD40/CD40L signaling
	Calcineurin-regulated NFAT-dependent transcription in lymphocytes
	Beta2 integrin cell surface interactions
	Calcium signaling in the CD4+ TCR pathway
Reactome	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
	TNFR2 non-canonical NF-kB pathway
	TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
WikiPathways	Inflammatory Response Pathway
	Allograft Rejection
	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 537129	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.